Pharmacodynamics and Drug Action
Clinical Pharmacology & Therapeutics (1997) 61, 459–466; doi:
Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype*
Gerd Mikus MD1, Beate Trausch MD1, Carsten Rodewald MD1, Ute Hofmann PhD1, Klaus Richter PhD1, Thomas Gramatté MD1 and Michel Eichelbaum MD1
1Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany, and Institut für Klinische Pharmakologie, Technische Universität Dresden, Dresden, Germany.
Correspondence: Gerd Mikus, MD, Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstrasse 112, 70376 Stuttgart, Germany.
*Supported by the Robert Bosch-Foundation, Stuttgart, Germany.
Received 19 August 1996; Accepted 24 October 1997.
Abstract
Background: Codeine is widely used as an analgesic and antitussive drug. The analgesic effect of codeine is mediated by its metabolite morphine, which is formed by the polymorphically expressed enzyme CYP2D6; therefore poor metabolizers have no analgesia after administration of codeine. Like other opiates, codeine causes a delay of gastric emptying and spastic constipation. It is not yet known whether the effect on gastrointestinal motility is mediated by codeine or its metabolite morphine.
Methods: To test the hypothesis that the metabolite morphine is responsible for the effects of codeine on gastrointestinal motility, a randomized, double-blind, two-way crossover study was performed. The orocecal transit time was studied in five extensive and five poor metabolizers of sparteine with the sulfasalazine-sulfapyridine method, assuming that no effects are observed in poor metabolizers because negligible amounts of morphine are formed.
Results: No differences of orocecal transit times were observed between extensive metabolizers and poor metabolizers after oral placebo administration. However, after oral codeine administration orocecal transit time was significantly prolonged in extensive metabolizer but not poor metabolizer subjects. All pharmacokinetic parameters of codeine showed no differences between extensive metabolizers and poor metabolizers. The pharmacokinetic parameters (mean
SD) of the metabolite morphine were significantly different between extensive metabolizer and poor metabolizer subjects (peak serum concentration, 13.9
10.5 versus 0.68
0.15 pmol/ml; area under the serum concentration-time curve, 27.8
16.0 versus 1.9
0.7 hr
pmol/ml; total amount of morphine excreted in urine, 0.160
0.036 versus 0.015
0.007
mol).
Conclusions: Because the orocecal transit time prolongation after codeine administration was observed only in extensive metabolizers, the effect of codeine on gastrointestinal motility, like the analgesia, is mediated by its metabolite morphine.
